

1 **The evaluation of factors affecting antibody response after**
2 **administration of the BNT162b2 vaccine: A prospective**
3 **study in Japan**

4
5 Toshiya Mitsunaga^{1,2}, Yuhei Ohtaki², Yutaka Seki^{1,3,4}, Masakata Yoshioka⁴, Hiroshi Mori⁵,
6 Midori Suzuka⁶, Syunsuke Mashiko², Satoshi Takeda², Kunihiro Mashiko¹

7
8 ¹ Department of Emergency Medicine, Association of EISEIKAI Medical and Healthcare
9 Corporation Minamitama Hospital, Tokyo, Japan

10 ² Department of Emergency Medicine, Jikei University School of Medicine, Tokyo, Japan

11 ³ Department of Cardiology, Association of EISEIKAI Medical and Healthcare Corporation
12 Minamitama Hospital, Tokyo, Japan

13 ⁴ Department of Internal Medicine, Association of EISEIKAI Medical and Healthcare
14 Corporation Minamitama Hospital, Tokyo, Japan

15 ⁵ Department of Medical Engineering, Association of EISEIKAI Medical and Healthcare
16 Corporation Minamitama Hospital, Tokyo, Japan

17 ⁶ Department of Pharmacy, Association of EISEIKAI Medical and Healthcare Corporation
18 Minamitama Hospital, Tokyo, Japan

19
20 Corresponding Author:

21 Toshiya Mitsunaga^{1,2}
22 3-10-1, Sanda-machi, Hachioji-city, Tokyo, 1930832, Japan
23 Email address: toshiya.m@jikei.ac.jp

24

25 **Abstract**

26 The aim of this study was to evaluate the antibody reaction after administration of the
27 BNT162b2 vaccine, and to reveal the factors that affect antibody production. This prospective
28 study was carried out in the Association of EISEIKAI Medical and Healthcare Corporation
29 Minamitama Hospital, in Tokyo, Japan, from April 15, 2021 to June 09, 2021. All our hospital's
30 workers who were administered the BNT162b2 vaccine as part of a routine program were
31 included in this study.

32 We calculated the anti-SARS-CoV-2 spike-specific antibody titer 1) before vaccination, 2)
33 seven to twenty days after the first vaccination, and 3) seven to twenty days after the second
34 vaccination.

35 The low-antibody titer group (LABG) was defined as the group having less than 25 percentiles
36 of antibody titer. Univariate and Multivariate logistic regression analysis were performed to
37 ascertain the effects of factors on the likelihood of LABG. 374 participants were eventually
38 included in our study, and they were divided into 94 LABG and 280 non-LABG. All samples
39 showed significant antibody elevation in the second antibody test, with a mean value of 3476
40 U/mL. When comparing the LABG and non-LABG groups, the median age, blood sugar, and
41 HbA1c were significantly higher in the LABG group. The rates of participants with low BMI
42 (<18.5) and high BMI (>30) were significantly higher in the LABG group. The proportion of
43 chronic lung disease, hypertension, diabetes, dyslipidemia, autoimmune disease, and cancer were
44 significantly higher in the LABG group. Although there was no significant difference confirmed
45 with respect to the exercise hours per day, the proportion of participants that did not perform
46 outdoor activities was significantly higher in the LABG group. The time interval between the
47 second vaccination and the second antibody test, and between the first and the second
48 vaccination was significantly longer in the non-LABG group.

49 Our logistic regression analysis revealed that the age, obesity, hypertension, diabetes,
50 dyslipidemia, antihypertensive drug, antilipid drug, γ -GT, BS, HbA1c, and lack of outdoor
51 activity were significant suppressors of antibody reaction, whereas maintaining the appropriate
52 time interval between the first and the second vaccination could promote a significant antibody
53 response. In the multivariate logistic regression analysis, age, obesity, and lack of outdoor
54 activities were significant suppressors of antibody reaction, whereas the length of days from the
55 first to the second vaccination promoted a significant antibody response.

56 Our single-center study demonstrates that age, obesity, and lack of outdoor activities were
57 significant suppressors of antibody response, whereas maintaining the appropriate time interval
58 between the first and the second vaccination could promote a significant antibody response.
59 Evidence from multi-center studies is needed to develop further vaccination strategies.

60
61
62
63
64
65
66
67
68
69
70

71 **Introduction**

72 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which started in Wuhan,
73 China, has spread all over the world significantly faster than we expected. By the end of April
74 2021, the number of cases infected with SARS-CoV-2 had exceeded 150 million, with more than
75 3.1 million deaths (mortality rate: 2.1%) (*World Health Organization, 2021*). According to the
76 the Ministry of Health, Labour and Welfare of Japan, the number of coronavirus 2019 (Covid-
77 19) cases confirmed by 30 April 2021 in Japan was 588,900, with 10,226 deaths (mortality rate:
78 1.74%) (*The Ministry of Health, Labour and Welfare, 2021*). Many developed countries in
79 cooperation with the World Health Organization (WHO) have been trying to reduce the number
80 of Covid-19 cases. However, because of its strong infectivity, it has been very challenging to
81 control this disease.

82 The majority of patients infected with Covid-19 were mild cases, but approximately 5% of cases
83 progressed to severe conditions, and approximately 2% died (*Li et al., 2020*). Several studies
84 have suggested that the risk factors for severe Covid-19 involve individual's age, gender (males
85 are at higher risk compared to females), smoking, and pre-existing conditions such as obesity,
86 diabetes, chronic lung disease, hypertension, dyslipidemia, and chronic kidney disease
87 (*Matsunaga et al., 2020; Mi et al., 2020; Liang et al., 2020; Lippi et al., 2020; Myers et al.,*
88 *2020; Fadini et al., 2020; Zheng et al., 2020; Popkin et al., 2020*). Although several treatment
89 strategies, including steroids and antiviral drugs, have been developed, vaccination is still the
90 most important means of preventing Covid-19 infection and aggravation in people with these
91 risk factors. BNT162b2 is a new generation vaccine with nucleoside-modified RNA molecules
92 encoding the full-length SARS-CoV-2 spike glycoprotein (*Polack et al., 2020*). A previous study
93 showed that the efficacy of this vaccine in preventing Covid-19 is approximately 95%, and thus
94 extremely high (*Polack et al., 2020*). Typically, people have to be vaccinated twice to boost their
95 immunity, and the study carried by Walsh *et al* showed that spike binding IgG titer increased
96 dramatically and reached a plateau after only seven days from the second dose (*Walsh et al.,*
97 *2020*). However, the major studies of Covid-19 vaccines are carried out in non-Asian countries,
98 and the true efficacy of this vaccine in Asian people is still unclear (*Polack et al., 2020; Walsh et*
99 *al., 2020*).

100 Certain studies have been identifying the factors that promote or suppress antibody response
101 after vaccination for several viruses. A study performed by Pellini *et al* showed that obesity and
102 age, which were the risk factors for severe Covid-19, may also be interfering factors for SARS-
103 CoV-2 vaccine immunogenicity (*Pellini et al., 2021*). However, the population of this study was
104 relatively small and only included non-Asian populations. In contrast, the studies performed by
105 Tanja *et al* and Prather *et al* demonstrated that sleep duration and sleep quality, which reflect the
106 circadian rhythm, were positively correlated to antibody production after Influenza vaccination
107 or Hepatitis A vaccination, respectively (*Tanja et al., 2003; Prather et al., 2021*). However, to
108 our knowledge, there have been no studies that evaluate the relationship between the factors
109 involved in the daily life rhythm and the antibody response after Covid-19 vaccination.

110 Therefore, the aim of this study was to evaluate the anti-SARS-CoV-2 spike-specific antibody
111 reaction following the administration of BNT162b2 vaccine, and to reveal the factors that affect
112 antibody response in a Japanese population.

113

114 **Materials & Methods**

115 **Study design**

116 This prospective study was carried out between April 15, 2021 and June 9, 2021 at the
117 Association of EISEIKAI Medical and Healthcare Corporation Minamitama Hospital, a
118 secondary emergency medical institution. The protocol for this research project was approved by
119 a suitably constituted Ethics Committee of the institution and conforms to the provision of the
120 Declaration of Helsinki (Committee of Association of EISEIKAI Medical and Healthcare
121 Corporation Minamitama Hospital, Approval No. 2020-Ack-19), and written consent was
122 obtained from all the human subjects.

123 **Study setting and population**

124 All our hospital's workers, who were administered with the BNT162b2 vaccine as part of a
125 routine program, were included in this study. The exclusion criteria were as follows: 1) cases that
126 we could not obtain informed consent, 2) cases with past Covid-19 infection, 3) cases whose
127 antibody titer before vaccination was elevated, 4) cases with new Covid-19 infection after
128 vaccination, and 5) cases who could not provide a blood sample within the expected deadline
129 (i.e., twenty days post-vaccination).

130 **Data sources and measurements**

131 A 5-ml blood sample was drawn from the intermediate cubital vein, and we determined the anti-
132 SARS-CoV-2 antibody titer (Elecsys[®] Anti-SARS-CoV-2 S RUO, Roche Diagnostics K.K.) a)
133 before vaccination (baseline), b) seven to twenty days after the first vaccination (first antibody
134 test), and c) seven to twenty days after the second vaccination (second antibody test). We
135 performed biochemical examinations (AST: aspartate aminotransferase, ALT: alanine
136 aminotransferase, γ -GT: γ -glutamyl transpeptidase, Alb: albumin, TG: triglyceride, HDL-C: high
137 density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, Cr: Creatinine, BS:
138 Blood Sugar, HbA1c: Hemoglobin A1c, CRP: C - reactive protein) and we also calculated the
139 blood cell count (White Blood Cells, Hemoglobin, Hematocrit, and Platelets) before vaccination.
140 Self-reports were used to register participants' information with respect to their age, gender,
141 height, body weight, body mass index (BMI), past medical histories (1. Chronic lung disease
142 (Chronic obstructive pulmonary disease: COPD), 2. Chronic lung disease (non-COPD), 3.
143 Cardiac disease, 4. Hypertension, 5. Diabetes, 6. Dyslipidemia, 7. Liver disease, 8. Chronic
144 kidney disease: CKD, 9. Autoimmune disease, 10. Cancer), medication (1. Antihypertensive
145 drug, 2. Antidiabetic drug, 3. Antilipid drug, 4. Antiplatelet and Anticoagulant drug, 5.
146 Immunosuppressive drug, 6. Immunoglobulin), smoking habits (current and past smoking
147 history), habits of drinking alcohol, sleep duration per day, the quality of sleep (good or
148 disturbed), number of meals per day, the quality of meal (good or disturbed), exercise hours per
149 day, the number of outdoor activity days per week, and the length of days for vaccination and
150 antibody test.

151 The diagnostic definition of the above diseases conformed to the WHO guideline, and we
152 defined obesity as follows: 1) Underweight: $BMI < 18.5$, 2) Normal range: $18.5 \leq BMI < 25$, 3)
153 Pre-obese: $25 \leq BMI < 30$, 4) Obese class I: $30 \leq BMI < 35$, 5) Obese class II: $35 \leq BMI < 40$,
154 6) Obese class III: $40 \leq BMI$ (*World Health Organization, 2020*).

155 The low-antibody titer group (LABG) was defined as the group having less than 25 percentiles
156 of antibody titer, whereas non-LABG was defined as having more than 25 percentiles of
157 antibody titer.

158 **Statistical analysis**

159 A sample size of 460 participants was determined based upon 70% power, 0.05 significance
160 level, 0.3 effect size, three allocation ration, and 20% attrition. Unadjusted analysis evaluated
161 between low and non-low-antibody titer group using the Student's *t* test and Mann–Whitney *U*

162 test for continuous variables, which were described as medians and interquartile ranges (IQR),
163 and Fisher's exact test or Pearson's χ^2 test for categorical variables, which were described as
164 numbers and percentages. Univariate and Multivariate logistic regression analysis was performed
165 to ascertain the effects of factors on the likelihood of LABG. Odds ratios and corresponding 95%
166 confidence intervals were calculated. A *p* value of less than 0.05 was considered to indicate
167 statistical significance. Data were analyzed with the Statistical Package for the Social Sciences,
168 version 26.0 (SPSS, Chicago, IL, USA).

169

170 **Results**

171 Of the 501 participants who fulfilled the inclusion criteria of this study, we excluded 96
172 participants because we did not obtain consents, seven participants because of past Covid-19
173 infection, one participant because of antibody titer elevation prior to the vaccination, one
174 participant because of new Covid-19 infection after vaccination, and 22 participants because they
175 could not provide a blood sample within the respective deadline. Finally, 374 participants were
176 analyzed that were divided into 94 LABG and 280 non-LABG (Fig 1).

177 The baseline characteristics are shown in Table 1. The median age (interquartile range) of the
178 participants was 36 (16.0) years, and 110 (29.4%) participants were males. Furthermore, 53
179 (14.2%) participants with pre-obesity (BMI: 25–30) and 19 (5.0%) participants with obesity
180 (BMI: >30) and zero participants belonging in the obese class III were identified. With respect to
181 comorbidities, 118 (31.6%) participants had past medical histories, chronic lung disease (35
182 cases: 9.4%), hypertension (30 cases: 8.0%), and dyslipidemia (16 cases: 4.3%). The median
183 duration (interquartile range) between the time from the first vaccination to the first antibody
184 test, and from the second vaccination to the second antibody test was eight (1) days. Moreover,
185 the median length of days from the first to the second vaccination was 22 (3) days.

186 Almost all antibody titer was not elevated in the first antibody test, and only 23 (6.2%) samples
187 exhibited a slight positive antibody response, with a mean value of 0.41 U/mL. All samples
188 showed significant antibody elevation in the second antibody test, with a mean value of 3476
189 U/mL (Fig 2).

190 Table 2 shows the comparison between LABG and non-LABG. The median age and HbA1c
191 were significantly higher in the LABG group ($p < 0.001$, < 0.01). The proportion of males (62
192 (33.2%) vs females (48 (25.7%)) was greater in the LABG group, but with no significant
193 differences ($p=0.38$). Moreover, the proportion of participants with low BMI (<18.5) and high
194 BMI (>30) were significantly higher in the LABG group ($p < 0.05$). The proportion of chronic
195 lung disease, hypertension, diabetes, dyslipidemia, autoimmune disease, and cancer was
196 significantly higher in the LABG group ($p < 0.05$). Although no significant difference was
197 confirmed in the hours of exercise per day, the proportion of participants with no-outdoor
198 activities was significantly higher in the LABG group ($p < 0.001$). Finally, the length of days
199 from the second vaccination to the second antibody test, and from the first to the second
200 vaccination was significantly longer in the non-LABG group ($p < 0.05$, < 0.05).

201 Table 3 shows the univariate and multivariate logistic regression analysis of the factors
202 associated with LABG. Age, obesity (obese class II), hypertension, diabetes, dyslipidemia,
203 antihypertensive drug, antilipid drug, γ -GT, BS, HbA1c, and lack of outdoor activity were a
204 significant suppressor of the antibody response. The univariate logistic regression analysis
205 revealed that the length of days from the first to the second vaccination promoted a significant
206 antibody response.

207 In addition, the multivariate logistic regression analysis, showed that age, obesity (obese class
208 II), and lack of outdoor activity were significant suppressors of the antibody response, whereas
209 the length of days from the first to the second vaccination was promoted a significant antibody
210 reaction.

211

212 Discussion

213 Our data showed that the antibody titer was dramatically elevated after the second administration
214 of the BNT162b2 vaccine in Japanese people. Moreover, our study identified that older age,
215 obesity (obese class II), and performing no-outdoor activities were significant suppressors of
216 antibody response, as opposed to the duration between the first and the second vaccination which
217 were found to promote a significant antibody response. This is the first study that evaluated the
218 antibody response in a relatively large cohort following mRNA vaccination for SARS-CoV-2 in
219 Japan, and assessed various factors in terms of promoting or suppressing a subsequent antibody
220 response.

221 According to previous studies, the median antibody titers were 9,136 or 27,872 U/ml at seven
222 days post-administration of the second vaccination, and 0.6 or 0.8 U/ml at seven days post-
223 administration of the first vaccination (*Walsh et al., 2020; Mulligan et al., 2020*). In the present
224 study, participants demonstrated a 6.2% and 100% positive antibody reaction for SARS-CoV-2
225 in the first and the second antibody test, respectively. The median antibody titers were 1.5 U/mL
226 in the first antibody test and 2620 U/mL in the second antibody test, values which are consistent
227 with current literature. Our findings demonstrate that the second dose of the BNT162b2 two-dose
228 vaccine can efficiently enhance the immunity of Asian people.

229 Several studies and guidelines showed that age, male, obesity, diabetes, chronic lung disease,
230 hypertension, dyslipidemia, chronic kidney disease and smoking were risk factors for the
231 development of severe Covid-19 (*Matsunaga et al., 2020; Mi et al., 2020; Liang et al., 2020;*
232 *Lippi et al., 2020; Myers et al., 2020; Fadini et al., 2020; Zheng et al., 2020; Popkin BM et al.,*
233 *2020*). A study performed by Pellini *et al* demonstrated that obesity, age and male sex may be
234 hampering SARS-CoV-2 vaccine immunogenicity (*Pellini et al., 2021*), but there was no other
235 similar study for comparison between vaccine immunogenicity and the factors affecting antibody
236 response.

237 Obesity, which also causes diabetes and hypertension, is one of the most important risk factors of
238 severe Covid-19 by suppressing immune system responses. In this study, we defined obesity in
239 accordance with the WHO guidelines (*World Health Organization, 2020*). A common definition
240 of obesity is important for comparing results of studies performed in different countries,
241 especially when it comes to the identification of immune responses pertaining to racial
242 differences. A previous review by Millner *et al* showed that the excess adipose tissue could block
243 the supply of nutrients to immune cells (*Milner et al., 2012*). Moreover, a study performed by
244 Vandanmagsar *et al* revealed that low levels of inflammation and relatively high levels of
245 inflammatory cytokines induced by adipose tissue can decrease immune responses, and
246 especially T lymphocyte activity (*Vandanmagsar et al., 2011*). These immune cell suppression
247 mechanisms can reduce the subsequent antibody production. Similar to these previous studies,
248 our data demonstrated that the rates of obesity (obese class II) were significantly larger in the
249 LABG group. Compared to the group with BMI of 35 or less, obesity (obese class II) had a
250 significantly higher odds ratio for low-antibody response, with a value of 28.01. Another
251 important question pertaining to obese participants was whether the vaccine solution was
252 actually injected into the muscle tissue. In the muscle tissue, the blood stream is abundant, large

253 numbers of immune cells are distributed in the muscle, thus the subsequent activation of
254 immunity by the vaccine can occur more easily. Moreover, intramuscular injection, as opposed
255 to subcutaneous injection, is definitely more critical for mRNA vaccines, because mRNA
256 vaccines are so fragile that they need to be quickly recognized by immune cells (**Zeng et al.,**
257 **2020**). According to the research by Akkus *et al* (**Akkus et al., 2012**), the maximum
258 subcutaneous adipose tissue thicknesses was approximately 18 mm for triceps, even when
259 participants' BMI is more than 30 kg/m². Furthermore, Takahashi *et al* presented a calculation
260 formula for the subcutaneous tissue thickness for triceps (Y) as follows; 1) male: $Y(\text{cm}) =$
261 $0.04X - 0.25$ and 2) female: $Y(\text{cm}) = 0.04X - 0.17$ ($X = \text{BMI}$) (**Takahashi et al., 2014**). The length
262 of the needle we used for vaccination was 25 mm, hence it was very unlikely that the needle
263 would not reach the muscle.

264 Similar to obesity, diabetes is also a significant risk factor element for the development of severe
265 Covid-19, and a report by Fadini *et al* showed that the presence of diabetes increases the risk by
266 2.3 times (**Fadini et al., 2020**). In addition, Berbudi *et al* showed that hyperglycemia could
267 inhibit IL-6 production, which induces antibodies and T cells (**Berbudi et al., 2020**), and that this
268 was a mechanism that triggered low-antibody production, similar to obesity. Our study showed
269 that the rates of diabetes, median blood sugar, and median HbA1c were significantly higher in
270 the LABG group. However, the subsequent adjustment did not reveal any significant differences
271 between the two groups.

272 Gustafson *et al* exhibited that the immune response toward vaccination is controlled by a delicate
273 balance of effector T cells and follicular T cells, yet the aging process disturbs this balance.
274 Several changes in T cells have been identified that contribute to age-related defects of post-
275 transcriptional regulation, T cell receptor signaling, and metabolic function (**Gustafson et al.,**
276 **2020**). Similar to Pellini's study, our study revealed that the antibody titer after mRNA SARS-
277 CoV-2 vaccine significantly reduces as older.

278 The Japanese Covid-19 guideline does not include gender in the risk factors for severe Covid-19,
279 but a report published overseas indicated that male patients are approximately three times more
280 likely to be admitted to intensive care units and have a higher mortality rate (**Mi et al., 2020**).

281 Females are known to be sensitive to immune responses, including antibody production to
282 infectious diseases, which in turn induces the development of autoimmune diseases (**Fischinger**
283 **et al., 2019**).

284 Differences in sex hormones are associated with gender differences in vaccine-induced
285 immunity. For example, testosterone levels and Influenza vaccine antibody titer have been
286 shown to be inversely correlated (**Markle et al., 2014; Ruggieri et al., 2016; Furman et al.,**
287 **2014**). Genetic differences, as well as sex hormone differences, affect vaccine-induced
288 immunity. The X chromosome expresses 10 times more genes than the Y chromosome, and
289 differences in gene expression between the X and Y chromosomes promote differences in
290 vaccine-induced immunity by gender (**Fischinger S et al., 2019**). Our study showed that
291 although not significant the proportion of males was larger in the LABG group, a finding that
292 agrees with current literature.

293 In contrast, several studies highlighting the relationship between smoking and vaccine-induced
294 immunological reactions, have been reported. However, the results of these studies vary and
295 none of them explains the underlying mechanism with which smoking influences antibody
296 production (**Winter et al., 1994; Namujju et al., 2014**). Certain studies showed that smoking
297 induced inflammatory cytokines and chemokines, but the effect of the complex mixture of
298 chemicals in tobacco varies depending on the individual smoking habits (**Kubo et al., 2005**;

299 *Daloe et al., 2017*). In our study, we did not identify any significant difference in smoking
300 between the LABG and non-LABG groups.
301 Furthermore, and although there was no difference in the exercise hours between the two groups,
302 including indoor activities, our study revealed that the proportion of no-outdoor activity days was
303 significantly larger in the LABG group. Moreover, participants that did not perform outdoor
304 activities had a significantly higher odds ratio, which was 2.38 after adjustment for LABG.
305 Researchers have long focused on the effect of vitamin D on the activation of the immune
306 system, and a study carried by Kashi *et al* showed that there was a positive correlation between
307 plasma vitamin D levels and post-vaccination antibody titer for Hepatitis B (*Kashi et al., 2021*).
308 Although no studies have further clarified the relationship between antibody titer and vitamin D
309 levels after vaccination for Covid-19, Merzon *et al* found that low plasma vitamin D levels or
310 short duration of exposure to sunlight were associated with an increased risk of Covid-19
311 infection (*Merzon et al., 2020*). Therefore, vitamin D levels may be positively correlated with
312 immune responses following administration of the BNT162b2 vaccine.
313 Two major studies showed that sleep duration and sleep quality were positively correlated to
314 antibody production after Influenza or Hepatitis A vaccination, respectively (*Tanja et al., 2003*;
315 *Prather et al., 2021*). However, to our knowledge, there have been no other studies that have
316 evaluated the effect of sleep to the triggering of antibody reactions after Covid-19 vaccination. In
317 our study, we could not show any significant relationship between sleep and antibody response.
318 Parry *et al.* showed that the antibody response was 3.5-fold higher in cases of delayed second
319 vaccination dose (12 weeks after he first vaccination), and the cellular immune responses were
320 3.6-fold lower compared to cases with normal vaccination schedule (*Parry et al., 2021*). Our
321 study revealed that a longer interval between the first and the second vaccination had a
322 significant positive correlation with antibody response.
323 The antibody titer level does not necessarily reflect the immune function against pathogens.
324 However, our study showed that lifestyle improvements such as performing outdoor activities
325 and reducing complications such as obesity may increase the immune response of the BNT162b2
326 vaccine, and this fact is especially important for people with risk factors for severe Covid-19. In
327 addition to this, further research of the vaccination schedule is also needed for promoting
328 immune responses after BNT162b2 vaccine administration, especially to older people.
329 Our study has several limitations. First, we only diagnosed new Covid-19 infections to
330 participants through symptoms of fever and common cold. Therefore, we were unable to identify
331 asymptomatic infections. However, our data showed that the number of antibody-positive cases
332 at baseline, without any previous episode of Covid-19 infection was only one (0.3%), and thus
333 had low statistical power. Second, we only calculated the antibody titer but not the CD4
334 lymphocyte activity. Consequently, we could not evaluate the effect of these factors to the entire
335 immune system. Third, we only included relatively healthy medical workers, but did not include
336 participants with severe complications, and this may have reduced the difference between the
337 LABG and non-LABG groups. Further large-scale studies that include participants with several
338 concurrent conditions are needed in the future.

339

340 **Conclusions**

341 Our single-center study demonstrated that age, obesity (obese class II), and lack of outdoor
342 activities were significant suppressors of antibody responses, whereas the length of days from the
343 first to the second vaccination promoted a significant antibody response. Evidence from multi-
344 center studies is needed to develop further vaccination strategies.

345

346 Acknowledgements

347 None

348

349 References

350 **World Health Organization. 2021.** WHO Coronavirus (COVID-19) Dashboard. Available
351 from: <https://covid19.who.int>

352 **The Ministry of Health, Labour and Welfare, Japan. 2021.** Coronavirus disease 2019
353 (COVID-19) situation within and outside the country. Available from:
354 http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/newpage_00032.html

355 **Li LQ, Huang Tian, Wang YQ, Wang ZP, Liang Y, Huang TB, Zhang HY, Sun W, Wang**
356 **Y. 2020.** COVID-19 patient's clinical characteristics, discharge rate, and fatality rate of
357 meta-analysis. *Journal of Medical Virology* 92(6): 577-583.

358 **Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, Suzuki S, Toyoda A,**
359 **Suzuki K, Endo M, Fujii N, Suzuki M, Saito S, Uemura Y, Shibata T, Kondo M, Izumi**
360 **K, Terada-Hirashima J, Mikami A, Sugiura W, Ohmagari N. 2020.** Clinical
361 epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19
362 REGISTRY JAPAN. *Clinical Infectious Diseases*. Available from:
363 <https://doi.org/10.1093/cid/ciaa1470>

364 **Mi J, Zhong W, Huang C, Zhang W, Tan L, Ding L. 2020.** Gender, age and comorbidities as
365 the main prognostic factors in patients with COVID-19 pneumonia. *American Journal of*
366 *Translational Research* 12(10): 6537-6548.

367 **Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J.**
368 **2020.** Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *The*
369 *LANCET Oncology* 21(3): 335-337.

370 **Lippi G, Henry BM. 2020.** Chronic obstructive pulmonary disease is associated with severe
371 coronavirus disease 2019 (COVID-19). *Respiratory Medicine* 167: 105941.

372 **Myers LC, Parodi SM, Escobar GJ, Liu VX. 2020.** Characteristics of Hospitalized Adults
373 With COVID-19 in an Integrated Health Care System in California. *JAMA* 323(21): 2195-
374 2198.

375 **Fadini GP, Morieri ML, Longato E, Avogaro A. 2020.** Prevalence and impact of diabetes
376 among people infected with SARS-Cov-2. *Journal of Endocrinological Investigation* 43(6):
377 867-869.

378 **Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, Li Q, Jiang C, Zhou Y, Liu S, Ye C, Zhang**
379 **P, Xing Y, Guo H, Tang W. 2020.** Risk factors of critical & mortal COVID-19 cases: A
380 systematic literature review and meta-analysis. *Journal of Infection* 81(2): e16-e25.

381 **Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, Alsukait RF, Alluhidan M,**
382 **Alazemi N, Shekar M. 2020.** Individuals with obesity and COVID-19: A global perspective
383 on the epidemiology and biological relationships. *Obesity Reviews* 21(11): e13128.

384 **Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Marc GP,**
385 **Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P,**
386 **Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S,**
387 **Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC. 2020.** Safety
388 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine*
389 383: 2603-2615.

390 **Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil**


- 391 **K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-**
392 **Garfias C, Shi PY, Türeci Ö, Tompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen**
393 **KU, Şahin U, Gruber WC. 2020.** Safety and Immunogenicity of Two RNA-Based Covid-
394 19 Vaccine Candidate. *New England Journal of Medicine* 383: 2439-50.
- 395 **Pellini R, Venuti A, Pimpinelli F, Abril E, Blandino G, Campo F, Conti L, Virgilio AD,**
396 **Marco FD, Domenico EGD, Bella OD, Martino SD, Ansoli F, Giannarelli D, Mandoj C,**
397 **Manciocco V, Marchesi P, Mazzola F, Morretto S, Petruzzi G, Petrone F, Pichi B,**
398 **Pontone M, Zocchi J, Vidiri A, Vujovic B, Piaggio G, Morrone A, Ciliberto G. 2021.**
399 Obesity may hamper SARS-CoV-2 vaccine immunogenicity. *medRxiv*. Doi:
400 <https://doi.org/10.1101/2021.0224.21251664>.
- 401 **Tanja L, Boris P, Horst FL, Jan B. 2003.** Sleep Enhances the Human Antibody Response to
402 Hepatitis A Vaccination. *Psychosomatic Medicine* 65(5): 831-835.
- 403 **Prather AA, Pressman SD, Miller GE, Cohen S. 2021.** Temporal Links Between Self-
404 Reported Sleep and Antibody Responses to the Influenza Vaccine. *International Journal of*
405 *Behavioral Medicine* 28: 151-158.
- 406 **World Health Organization. 2020.** Obesity and overweight. Available from:
407 <https://www.who.int/news-room/fact-she>.
- 408 **Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V,**
409 **Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY,**
410 **Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC,**
411 **Şahin U, Jansen KU. 2020.** Phase I/II study of COVID-19 RNA vaccine BNT162b1 in
412 adults. *Nature* 586(7830): 589-593.
- 413 **Milner JJ, Beck MA. 2012.** Micronutrients, immunology and inflammation. The impact of
414 obesity on the immune response to infection. *Proceedings of the Nutrition Society* 71: 298-
415 306.
- 416 **Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Rayussin E,**
417 **Stephens JM, Dixit VD. 2011.** The NLRP3 inflammasome instigates obesity-induced
418 inflammation and insulin resistance. *Nature Medicine* 17(2):179-188.
- 419 **Zeng C, Zhang C, Walker PG, Dong Y. 2020.** Formulation and Delivery Technologies for
420 mRNA Vaccines. *Current Topics in Microbiology and Immunology*
421 https://doi.org/10.1007/82_2020_217
- 422 **Akkus O, Oguz A, Uzunlulu M, Kizilgul M. 2012.** Evaluation of Skin and Subcutaneous
423 Adipose Tissue Thickness for Insulin Injection. *Journal of Diabetes and Metabolism* 3(8):
424 216.
- 425 **Takahashi Y, Kikuchi K, Miura N, Ishida Y. 2014.** Appropriate Needle Insertion Depth for
426 Intramuscular Injection Based on Assessment of BMI. *Journal of Japan Academy of Nursing*
427 *Science* 34: 36-45.
- 428 **Fadini GP, Morieri ML, Longato E, Avogaro A. 2020.** Prevalence and impact of diabetes
429 among people infected with SARS-CoV-2. *Journal of Endocrinological Investigation*
430 43(6): 867-869.
- 431 **Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. 2020.** Type 2 Diabetes and its Impact on
432 the Immune System. *Current Diabetes Review* 16(5): 442-449.
- 433 **Gustafson CE, Kim C, Weyand CM, Goronzy JJ. 2020.** Influence of immune aging on
434 vaccine responses. *Journal of Allergy and Clinical Immunology* 145(5): 1309-1321.
- 435 **Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. 2019.** Sex differences in
436 vaccine-induced humoral immunity. *Seminars in immunopathology* 41: 239-249.

- 437 **Markle JG, Fish EN. SeXX matters in immunity. 2014.** Trends in Immunology 35: 97-104.
- 438 **Ruggieri A, Anticoli S, D' Ambrosio A, Giordani L, Viora M. 2016.** The influence of sex and
- 439 gender on immunity, infection and vaccination. Annali Ist Super Sanita 52: 198-204.
- 440 **Furman D, Hejblum BP, Simon N, Jojic V, Dekker CL, Thiébaud R, Tibshirani RJ, Davis**
- 441 **MM. 2014.** Systems analysis of sex differences reveals an immunosuppressive role for
- 442 testosterone in the response to influenza vaccination. Proceedings of the Natinonal Academy
- 443 of Sciences of the United States of America 111(2): 869-874.
- 444 **Winter AP, Follett EAC, McIntyre J, Stewart J, Symington IS. 1994.** Influence of smoking
- 445 on immunological responses to hepatitis B vaccine. Vaccine 12(9): 771-772.
- 446 **Namujju PB, Pajunen E, Simen-Kapeu A, Hedman L, Merikukka M, Surcel HM,**
- 447 **Kirnbauer R, Apter D, Paavonen J, Hedman K, Lehtinen M. 2014.** Impact of smoking on
- 448 the quantity and quality of antibodies induced by human papillomavirus type 16 and 18
- 449 AS04-adjuvanted virus-like-particle vaccine – a pilot study. BMC Research Notes 7: 445.
- 450 **Kubo S, Kobayashi M, Masunaga Y, Ishii H, Hirano Y, Takahashi K, Shimizu Y. 2005.**
- 451 Cytokine and chemokine expression in cigarette smoke-induced lung injury in guinea pigs.
- 452 European Respiratory Journal 26: 993-1001.
- 453 **Daloe MH, Avan A, Mirhafez SR, Kavousi E, Hasanian-Mehr M, Darroudi S, Tajfard M,**
- 454 **Tayefi M, Qazizade H, Mohammadi A, Ferydouni N, Ebrahimi M, Ghayour-Mobarhan**
- 455 **M. 2017.** Impact of Cigarette Smoking on Serum Pro- and Anti- Inflammatory Cytokines and
- 456 Growth Factors. American Journal of Men's Health 11(4): 1169-1173.
- 457 **Kashi DS, Oliver SJ, Wentz LM, Roberts R, Carswell AT, Tang JCY, Jackson S, Izard**
- 458 **RM, Allan D, Rhodes LE, Fraser WD, Greeves JP, Walsh NP. 2021.** Vitamin D and the
- 459 hepatitis B vaccine response: a retrospective cohort study and a randomized, placebo-
- 460 controlled oral vitamin D3 and simulated sunlight supplementation trial in healthy adults.
- 461 European Journal of Nutrition 60: 475-491.
- 462 **Merzon E, Tworowski D, Gorohovski A, Vinker S, Cohen AG, Green I, Frenkel-**
- 463 **Morgenstern M. 2020.** Low plasma 25(OH) vitamin D level is associated with increased
- 464 risk of COVID-19 infection: an Israeli population-based study. The FEBS Journal 287(17):
- 465 3693-3702.
- 466 **Parry H, Bruton R, Stephens C, Brown K, Amirthalingam G, Hallis B, Otter A, Zuo J,**
- 467 **Moss P. 2021.** Extended interval BNT162b2 vaccination enhanced peak antibody generation
- 468 in older people. medRxiv. Doi: <https://doi.org/10.1101/2021.05.15.21257017>.
- 469
- 470
- 471
- 472
- 473
- 474
- 475
- 476
- 477
- 478
- 479
- 480
- 481

482 **Figure Legends**

483


484 **Figure 1. Flowchart for sample selection.**



485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506

507 **Figure 2. Anti-SARS-CoV-2 spike-specific antibody response to BNT162b2 vaccination.**

508 374 participants were administered the BNT162b2 vaccine. Serum samples were obtained before
509 injection and 7 to 20 days after the first and second vaccination. Each bar shows the geometric
510 mean concentrations of anti-SARS-CoV-2 spike-specific antibody (lower limit of quantitation,
511 0.40; dashed line). The top of the vertical bar represents the mean with a 95% confidence interval
512 (I bar). For values below the lower limit of quantification (LLOQ)=0.40, LLOQ/2 were included
513 in the calculation.



514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531

532 **Table 1. Baseline characteristics of the study population.**

	Total Population (n=374) Median (interquartile range)
Age, years	36 (16.0)
Sex [n (%)]	
Male	110 (29.4)
Female	264 (70.6)
Body Mass Index (BMI), kg/m ²	
BMI < 18.5	34 (9.1)
18.5 ≤ BMI <25	268 (71.7)
25 ≤ BMI <30	53 (14.2)
30 ≤ BMI <35	14 (3.7)
35 ≤ BMI <40	5 (1.3)
Past Medical Histories [n (%)]	
Chronic lung disease (COPD)	1 (0.3)
Chronic lung disease (non-COPD)	34 (9.1)
Cardiac disease	6 (1.6)
Hypertension	30 (8.0)
Diabetes	6 (1.6)
Dyslipidemia	16 (4.3)
Liver disease	6 (1.6)
Chronic kidney disease	4 (1.1)
Autoimmune disease	7 (1.9)
Cancer	8 (2.1)
Medication [n (%)]	
Antihypertensive drug	28 (7.5)
Antidiabetic drug	5 (1.3)
Antilipid drug	13 (3.5)
Anticoagulant / Antiplatelet drug	2 (0.5)
Immunosuppressive drug	3 (0.8)
Immunoglobulin	4 (1.1)

Current smoking [n (%)]	70 (18.7)
Past smoking [n (%)]	64 (17.1)
Drinking Alcohol [n (%)]	229 (61.2)
Laboratory test	
WBC	6.35 (2.0)
Hb	13.9 (1.7)
Hct	40.2 (4.5)
PLT	25.2 (7.3)
Alb	4.6 (0.4)
AST	19.0 (6.0)
ALT	15.0 (12.0)
γ -GT	17.0 (12.8)
Cr	0.6 (0.2)
CRP	0.03 (0.05)
BS	90 (13.0)
HbA1c	5.5 (0.4)
HDL-C	65.0 (19.0)
LDL-C	107 (35.0)
TG	74.0 (59.0)
Sleep duration (SD) [n (%)]	
SD \leq 2 hours	1 (0.3)
3 hours \leq SD < 4 hours	64 (17.1)
5 hours \leq SD < 7 hours	297 (79.4)
8 hours \leq SD < 10 hours	12 (3.2)
The quality of sleep [n (%)]	
Good	232 (62.0)
Disturbed	142 (38.0)
The number of meals per day [n (%)]	
Once	1 (0.3)
Twice	104 (27.8)

More than 3 times	269 (71.9)
The exercise hours (EH) per day [n (%)]	
EH < 30 minutes	271 (72.5)
30 minutes \leq EH < 1 hour	79 (21.1)
1 hour \leq EH	24 (6.4)
The numbers of outdoor activity days per week [n (%)]	
No	199 (53.2)
More than once	175 (46.8)
The length of days for vaccination and antibody test, days	
1st vaccination to 1st antibody test	8 (1)
2nd vaccination to 2nd antibody test	8 (1)
1st vaccination to 2nd vaccination	22 (3)

533 Data are presented as the median (interquartile range) for continuous variables and the number
 534 (%) for categorical variables. COPD, Chronic obstructive pulmonary disease; WBC, White blood
 535 cells; Hb, Hemoglobin; Hct, Hematocrit; PLT, Platelets; Alb, Albumin; AST, Aspartate
 536 aminotransferase; ALT, alanine aminotransferase; γ -GT, γ -glutamyl transpeptidase; Cr,
 537 Creatinine; CRP, C-reactive protein; BS, Blood sugar; HbA1c, Hemoglobin A1c; HDL-C, High
 538 density lipoprotein cholesterol; LDL-C, Low density lipoprotein cholesterol; TG, Triglyceride.
 539

540
 541
 542
 543
 544
 545
 546
 547
 548
 549
 550
 551
 552
 553
 554
 555
 556
 557

558 **Table 2. Comparison of parameters between LABG and non-LABG**

	Median (interquartile range)		<i>p</i> value
	LABG (n=94)	non-LABG (n=280)	
Age, years	41.5 (16.0)	35 (15.0)	< 0.001
Sex [n (%)]			0.38
Male	31 (33.0)	79 (28.2)	
Female	63 (67.0)	201 (71.8)	
Body Mass Index: BMI [n (%)]			< 0.05
BMI < 18.5	12 (12.8)	22 (7.9)	
18.5 ≤ BMI <25	61 (64.9)	207 (73.9)	
25 ≤ BMI <30	14 (14.9)	39 (13.9)	
30 ≤ BMI <35	3 (3.2)	11 (3.9)	
35 ≤ BMI <40	4 (4.3)	1 (0.4)	
Past Medical Histories [n (%)]			< 0.05
Chronic lung disease (COPD)	1 (1.1)	0 (0)	
Chronic lung disease (non-COPD)	11 (11.7)	23 (8.2)	
Cardiac disease	0 (0.0)	6 (2.1)	
Hypertension	15 (16.0)	15 (5.4)	
Diabetes	5 (5.3)	1 (0.4)	
Dyslipidemia	9 (9.6)	7 (2.5)	
Liver disease	2 (2.1)	4 (1.4)	
Chronic kidney disease	0 (0.0)	4 (1.4)	
Autoimmune Disease	4 (4.3)	3 (1.1)	
Cancer	3 (3.2)	5 (1.8)	
Medication [n (%)]			0.08
Antihypertensive drug	13 (13.8)	15 (5.4)	
Antidiabetic drug	5 (5.3)	0 (0.0)	
Antilipid drug	8 (8.5)	5 (1.8)	
Anticoagulant / Antiplatelet drug	1 (1.1)	1 (0.4)	
Immunosuppressive drug	1 (1.1)	2 (0.7)	
Immunoglobulin	4 (4.3)	0 (0.0)	

Smoking [n (%)]			
Current smoking [n (%)]	20 (21.3)	50 (17.9)	0.74
Past smoking [n (%)]	20 (21.3)	44 (15.7)	
Drinking Alcohol [n (%)]	62 (66.0)	167 (59.6)	0.28
Laboratory test			
WBC	6.4 (2.4)	6.3 (1.9)	0.94
Hb	14.1 (1.4)	13.8 (1.9)	0.37
Hct	40.9 (4.5)	40.0 (4.3)	0.44
PLT	25.2 (6.8)	25.2 (7.3)	0.99
Alb	4.6 (0.4)	4.6 (0.4)	0.06
AST	19.0 (7.5)	19.0 (5.0)	0.20
ALT	17.0 (11.8)	15.0 (11.0)	0.05
γ -GT	19.0 (16.0)	16.0 (11.3)	< 0.001
Cr	0.66 (0.2)	0.63 (0.2)	0.67
CRP	0.03 (0.04)	0.03 (0.05)	0.29
BS	91.0 (17.5)	90.0 (12.0)	0.05
HbA1c	5.6 (0.5)	5.5 (0.4)	< 0.01
HDL-C	65.0 (20.0)	65.0 (19.0)	0.90
LDL-C	107.0 (33.8)	107.0 (36.0)	0.80
TG	75.0 (65.5)	73.0 (54.0)	0.67
Sleep duration (SD) [n (%)]			
SD \leq 2 hours	1 (1.1)	0 (0)	0.33
3 hours \leq SD < 4 hours	16 (17.0)	48 (17.1)	
5 hours \leq SD < 7 hours	75 (79.8)	222 (79.3)	
8 hours \leq SD < 10 hours	2 (2.1)	10 (3.5)	
The quality of sleep [n (%)]			
Good	57 (60.6)	175 (62.5)	0.75
Disturbed	37 (39.4)	105 (37.5)	
The exercise hours (EH) per day [n (%)]			
EH < 30 minutes	66 (70.2)	205 (73.2)	0.82
30 minutes \leq EH < 1 hour	22 (23.4)	57 (20.4)	

1 hour \cong EH	6 (6.4)	18 (6.4)	
The numbers of outdoor activity days per week [n (%)]			< 0.001
No	64 (68.1)	135 (48.2)	
More than once	30 (31.9)	145 (51.8)	
The length of days from vaccination to antibody test, days			
1st vaccination to 1st antibody test	8 (1)	8 (1)	0.90
2nd vaccination to 2nd antibody test	8 (0)	8 (1)	< 0.05
1st vaccination to 2nd vaccination	22 (2)	22 (3)	< 0.05

559 Data are presented as the median (interquartile range) for continuous variables and the number
 560 (%) for categorical variables. COPD, Chronic obstructive pulmonary disease; WBC, White blood
 561 cells; Hb, Hemoglobin; Hct, Hematocrit; PLT, Platelets; Alb, Albumin; AST, Aspartate
 562 aminotransferase; ALT, alanine aminotransferase; γ -GT, γ -glutamyl transpeptidase; Cr,
 563 Creatinine; CRP, C-reactive protein; BS, Blood sugar; HbA1c, Hemoglobin A1c; HDL-C, High
 564 density lipoprotein cholesterol; LDL-C, Low density lipoprotein cholesterol; TG, Triglyceride.

565
 566
 567
 568
 569
 570
 571
 572
 573
 574
 575
 576
 577
 578
 579
 580
 581
 582
 583
 584
 585
 586
 587
 588

589 **Table 3. Univariate and multivariate logistic regression analysis of factors associated with**
 590 **low-antibody titer after vaccination.**

Predictor	Unadjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value
Age, years	1.06 (1.03-1.08)	p < 0.001	1.05 (1.02-1.08)	p < 0.001
Sex [n (%)]				
Male	1.25 (0.76-2.07)	0.38		
Body Mass Index: BMI [n (%)]				
BMI < 18.5	1.72 (0.81-3.62)	0.16		
18.5 ≤ BMI <25	0.65 (0.40-2.81)	0.09		
25 ≤ BMI <30	1.08 (0.56-2.09)	0.82		
30 ≤ BMI <35	0.81 (0.22-2.95)	0.75		
35 ≤ BMI <40	12.40 (1.37-112.38)	p < 0.05	28.01 (1.81-433.84)	p < 0.05
Past Medical Histories [n (%)]				
Chronic lung disease (COPD and non-COPD)	1.64 (0.78-3.43)	0.19		
Hypertension	3.35 (1.57-7.16)	p < 0.01	3.17 (0.64-15.80)	0.16
Diabetes	15.67 (1.81-135.95)	p < 0.05	6.86 (0.30-154.79)	0.23
Dyslipidemia	4.13 (1.49-11.42)	p < 0.01	1.04 (0.23-4.80)	0.96
Liver disease	1.50 (0.27-8.32)	0.64		
Autoimmune Disease	4.10 (0.90-18.68)	0.07		
Cancer	1.81 (0.43-7.74)	0.42		
Medication [n (%)]				
Antihypertensive drug	2.84 (1.30-6.21)	p < 0.01	0.44 (0.08-2.56)	0.36
Antilipid drug	5.12 (1.63-16.05)	p < 0.01	1.51 (0.29-7.98)	0.63
Anticoagulant / Antiplatelet drug	3.00 (0.19-48.44)	0.44		
Immunosuppressive drug	1.49 (0.13-16.67)	0.74		
Smoking [n (%)]				
Current smoking [n (%)]	1.24 (0.70-2.22)	0.46		
Past smoking [n (%)]	1.45 (0.80-2.61)	0.22		
Drinking Alcohol [n (%)]	1.31 (0.80-2.14)	0.28		

Laboratory test				
WBC	1.01 (0.88-1.18)	0.85		
Hb	1.01 (0.86-1.20)	0.90		
Hct	1.03 (0.96-1.10)	0.44		
PLT	1.00 (0.97-1.05)	0.67		
Alb	0.53 (0.27-1.04)	0.06		
AST	1.02 (0.99-1.05)	0.18		
ALT	1.01 (1.00-1.03)	0.16		
γ -GT	1.01 (1.00-1.03)	p < 0.01	1.01 (1.00-1.02)	0.095
Cr	1.74 (0.37-8.21)	0.48		
CRP	1.37 (0.51-3.63)	0.53		
BS	1.01 (1.00-1.03)	p < 0.05	1.01 (1.00-1.03)	0.14
HbA1c	1.99 (1.24-3.20)	p < 0.01	0.67 (0.33-1.38)	0.28
HDL-C	1.00 (0.98-1.02)	0.93		
LDL-C	1.00 (0.99-1.01)	0.89		
TG	1.00 (1.00-1.00)	0.68		
Sleep duration (SD) [n (%)]				
SD < 4 hours	1.07 (0.58-1.96)	0.83		
5 hours \leq SD < 7 hours	1.03 (0.58-1.84)	0.92		
8 hours \leq SD < 10 hours	0.59 (0.13-2.73)	0.50		
The quality of sleep [n (%)]				
Disturbed	1.08 (0.67-1.75)	0.75		
The exercise hours (EH) per day [n (%)]				
EH < 30 minutes	0.86 (0.51-1.44)	0.57		
30 minutes \leq EH < 1 hour	1.20 (0.68-2.10)	0.53		
1 hour \leq EH	0.99 (0.38-2.58)	0.99		
The numbers of outdoor activity days per week [n (%)]				
No	2.29 (1.40-3.75)	p < 0.001	2.38 (1.39-4.09)	p < 0.01
The length of days from vaccination to antibody test, days				
1st vaccination to 1st antibody test	0.97 (0.77-1.23)			

2nd vaccination to 2nd antibody test	0.77 (0.59-1.01)	0.06		
1st vaccination to 2nd vaccination	0.864 (0.78-0.96)	p < 0.01	0.85 (0.76-0.96)	p < 0.01

591 COPD, Chronic obstructive pulmonary disease; WBC, White blood cells; Hb, Hemoglobin; Hct,
592 Hematocrit; PLT, Platelets; Alb, Albumin; AST, Asparate aminotransferase; ALT, alanine
593 aminotransferase; γ -GT, γ -glutamyl transpeptidase; Cr, Creatinine; CRP, C-reactive protein; BS,
594 Blood sugar; HbA1c, Hemoglobin A1c; HDL-C, High density lipoprotein cholesterol; LDL-C,
595 Low density lipoprotein cholesterol; TG, Triglyceride.
596